Renal function to 5 years after late conversion of kidney transplant patients to everolimus: a randomized trial
Tóm tắt
Few trials have investigated late preemptive conversion of kidney transplant patients from a calcineurin inhibitor (CNI) to an mTOR inhibitor. In an open-label, 12-month, prospective, randomized, parallel-group study, maintenance kidney transplant patients (>6 months post-transplant) either switched from CNI to everolimus or continued their current CNI regimen. Patients who completed the core study were followed to 5 years post-randomization. Of 93 randomized patients, 78 completed the core study and 67 attended the final 60-month study visit. Mean time post-transplant at baseline was 82.6 months and 70.5 months in the everolimus and CNI groups, respectively. At month 60, adjusted mean eGFR (Nankivell) was 63.0 (95 % CI 57.8, 68.2) mL/min/1.73 m2 in the everolimus group versus 57.9 (95 % CI 52.6, 63.1) mL/min/1.73 m2 in the CNI group, a difference of 5.1 (95 % CI −0.6, 10.8) mL/min/1.73 m2 (p = 0.076). Among patients who remained on randomized study drug at month 60, mean eGFR (Nankivell) was 71.6 (95 % CI 64.2, 79.0) mL/min/1.73 m2 in everolimus-treated patients (n = 21) versus 60.6 (95 % CI 55.1, 66.1) mL/min/1.73 m2 in CNI-treated patients (n = 29) (mean difference 11.0; 95 % CI 3.6, 18.5 mL/min/1.73 m2; p = 0.005). No cases of BPAR occurred from randomization to month 60 in either group. Graft loss occurred in three everolimus-treated patients and one CNI-treated patient. No unexpected safety concerns were observed in either group. Late preemptive conversion of maintenance kidney transplant patients from CNI to everolimus may be associated with improved long-term renal function and preserves immunosuppressive efficacy. Patient numbers were low, but these findings merit further investigation.
Tài liệu tham khảo
Campistol JM, de Fijter JW, Nashan B, Holdaas H, Vítko S, Legendre C (2011) Everolimus and long-term outcomes in renal transplantation. Transplantation 92(3 Suppl):S3–S26
Holdaas H, Midtvedt K, Åsberg A (2012) A drug safety evaluation of everolimus in kidney transplantation. Expert Opin Drug Saf 11:1013–1022
Halleck F, Duerr M, Waiser J et al (2012) An evaluation of sirolimus in renal transplantation. Expert Opin Drug Metab Toxicol 8:1337–1356
Chapman JR (2011) Chronic calcineurin inhibitor nephrotoxicity-lest we forget. Am J Transplant 11:693–697
Ojo A, Held PHJ, Port FK et al (2003) Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 349:931–940
Vitko S, Tedesco H, Eris J et al (2004) Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 4:626–635
Chan L, Greenstein S, Hardy MA, CRADUS09 Study Group et al (2008) Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 85:821–826
Tedesco Silva H Jr, Cibrik D, Johnston T et al (2010) Everolimus plus reduced-exposure CsA versus mycophenolic acid plus standard-exposure CsA in renal-transplant recipients. Am J Transplant 10:1401–1413
Albano L, Berthoux F, Moal MC, RAD A2420 Study Group et al (2009) Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus. Transplantation 88:69–76
Cibrik D, Silva HT, Vathsala A et al (2013) Randomized trial of everolimus-facilitated calcineurin-inhibitor minimization over 24 months in renal transplantation. Transplantation 95:933–942
Nankivell BJ, Borrows RJ, Fung CL, O’Connell PJ, Chapman JR, Allen RD (2004) Calcineurin inhibitor nephrotoxicity: longitudinal assessment by protocol histology. Transplantation 78:557–565
Guba M, Pratschke J, Hugo C, SMART-Study Group et al (2010) Renal function, efficacy, and safety of sirolimus and mycophenolate mofetil after short-term calcineurin inhibitor-based quadruple therapy in de novo renal transplant patients: one-year analysis of a randomized multicenter trial. Transplantation 90:175–183
Mjörnstedt L, Sørensen SS, von Zur Mühlen B et al (2012) Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant 12:2744–2753
Lebranchu Y, Thierry A, Toupance O et al (2009) Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: CONCEPT study. Am J Transplant 9:1115–1123
Weir MR, Mulgaonkar S, Chan L et al (2011) Mycophenolate mofetil-based immunosuppression with sirolimus in renal transplantation: a randomized, controlled Spare-the-Nephron trial. Kidney Int 79:897–907
Budde K, Becker T, Arns A et al (2011) Everolimus-based regimen calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 377:837–847
Chadban S, Eris J, Kanellis J, The SOCRATES Study Group et al (2013) A randomized, controlled trial of everolimus based dual immunosuppression vs standard of care in de novo kidney transplant recipients. Transpl Int. doi:10.1111/tri.12252
Silva HT Jr, Felipe CR, Garcia VD et al (2013) Planned randomized conversion from tacrolimus to sirolimus-based immunosuppressive regimen in de novo kidney transplant recipients. Am J Transplant 13:3155–3163
Schena FP, Pascoe MD, Alberu J, Sirolimus CONVERT Trial Study Group et al (2009) Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 87:233–242
Holdaas H, Rostaing L, Serón D, ASCERTAIN Investigators et al (2011) Conversion of long-term kidney transplant recipients from calcineurin inhibitor therapy to everolimus: a randomized, multicenter, 24-month study. Transplantation 92:410–418
Rostaing L, Kamar N (2010) mTOR inhibitor/proliferation signal inhibitors: entering or leaving the field? J Nephrol 23:133–142
Budde K, Sommerer C, Haller H et al (2014) Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clin Transplant (submitted)
Nankivell BJ, Gruenewald SM, Allen R, Chapman JR (1995) Predicting glomerular filtration rate after kidney transplantation. Transplantation 59:1683–1689
Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
Poggio ED, Wang X, Weinstein DM et al (2006) Assessing glomerular filtration rate by estimation equations in kidney transplant recipients. Am J Transplant 6:100–108
Flechner SM, Goldfarb D, Modlin C et al (2002) Kidney transplantation without calcineurin inhibitor drugs: a prospective, randomized trial of sirolimus versus cyclosporine. Transplantation 74:1070–1076
Johnson RWG, Kreis H, Oberbauer R, Brattström C, Claesson K, Eris J (2001) Sirolimus allows early cyclosporine withdrawal in renal transplantation resulting in improved renal function and lower blood pressure. Transplantation 72:777–786
Diekmann F, Andrés A, Oppenheimer F (2012) mTOR inhibitor-associated proteinuria in kidney transplant recipients. Transplant Rev 26:27–29
Sánchez-Fructuoso AI, Ruiz JC, Calvo N, Rodrigo E et al (2012) Everolimus as primary immunosuppression in kidney transplantation: experience in conversion from calcineurin inhibitors. Transplantation 93:398–405
Marx C, Busch M, Ott U, Gerth J, Wolf G (2010) Proteinuria after conversion to sirolimus in kidney transplant recipients: impact of pre-existing proteinuria, graft function, and angiotensin-converting enzyme inhibitors/angiotensin-receptor antagonists. Clin Transplant 24:626–630
Wali RK, Mohanlal V, Ramos E et al (2007) Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 7:1572–1583
Organ Procurement and Transplant Network Annual Data Report 2011. http://optn.transplant.hrsa.gov/news/newsDetail.asp?id=1589
Gondos A, Döhler B, Brenner H, Opelz G (2013) Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation 95:267–274